Search results for "OUTCOMES"

showing 10 items of 446 documents

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia

2020

Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Fa…

medicine.medical_specialty030232 urology & nephrologyUrologyRenal functionType 2 diabetes030204 cardiovascular system & hematologyoutcomesNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusClinical endpointMedicineDapagliflozinAcademicSubjects/MED00340Editorial CommentsCanagliflozinTransplantationclinical trialsbusiness.industrySGLT2 inhibitormedicine.diseasemortalitychemistryNephrologybusinesschronic kidney diseaseKidney diseasemedicine.drugClinical Kidney Journal
researchProduct

Standard and Specialized Infant Formulas in Europe: Making, Marketing, and Health Outcomes

2019

Infant formulas are the only suitable substitute for human milk. The most common infant formulas are standard formulas based on cow's milk. In addition, there are formulas for infants showing signs and symptoms of intolerance and for clinical conditions such as allergy, prematurity, and gastrointestinal diseases. A comprehensive review of the literature was made to review the composition of standard and specialized infant formulas and analyze indications for use, real or presumed nutrition differences and properties, and impact on infant growth. A brief consideration on costs is outlined for each formula. Over the past few years, industrial production and advertising of infant formulas have…

medicine.medical_specialty030309 nutrition & dieteticsBreastfeedingMedicine (miscellaneous)Signs and symptomsHealth outcomes03 medical and health sciences0302 clinical medicineOutcome Assessment Health CaremedicineAnimalsHumansenteral nutritionIntensive care medicineInfant Nutritional Physiological PhenomenaFood FormulatedMarketing0303 health sciencesNutrition and DieteticsMilk Humaninfant nutritionbusiness.industryInfant Newbornhuman milkInfant nutritioninfant formulaNutrientsinfantEuropeParenteral nutritionBreast FeedingMilkInfant formula030211 gastroenterology & hepatologyenteral nutrition; human milk; infant; infant formula; infant nutritionbusiness
researchProduct

A systematic review of the accuracy and efficiency of dental movements with Invisalign®

2019

We are currently living in an era where the use of computer-aided design/computer-aided manufacturing has allowed individualized orthodontic treatments, but has also incorporated enhanced digitalized technology that does not permit improvisation. The purpose of this systematic review was to analyze publications that assessed the accuracy and efficiency of the Invisalign® system. A systematic review was performed using a search strategy to identify articles that referenced Invisalign®, which were published between August 2007 and August 2017, and listed in the following databases: MEDLINE, Embase, Cochrane Library, Web of Knowledge, Google Scholar, and LILACS. Additionally, a manual search o…

medicine.medical_specialty050402 sociologyInvisalign®business.industry05 social sciencesMEDLINEOrthodonticsTreatment outcomes030206 dentistryEvidence-based medicineReview ArticleTechnology assessmentCochrane LibraryClinical trialInvisible orthodontics03 medical and health sciences0302 clinical medicine0504 sociologyWeb of knowledgeHealth careMedicineMedical physicsbusinessMethodological qualityClear alignersKorean Journal of Orthodontics
researchProduct

Use of corticosteroids in Coronavirus disease 2019 pneumonia: A systematic review of the literature

2020

The aim was to investigate the effectiveness of glucocorticoid therapy in patients with COVID-19. A systematic search of the literature across nine databases was conducted from inception until 15th March 2020, following the PRISMA guidelines. Patients with a validated diagnosis of COVID-19 and using corticosteroids were included, considering all health outcomes. Four studies with 542 Chinese participants were included. Two studies reported negative findings regarding the use of corticosteroids in patients with COVID-19, i.e., corticosteroids had a detrimental impact on clinical outcomes. One study reported no significant association between the use of corticosteroids and clinical outcomes. …

medicine.medical_specialtyARDSCoronavirus disease 2019 (COVID-19)SARS-Cov-2Coronavirucoronavirus030204 cardiovascular system & hematologyHealth outcomescorticosteroids03 medical and health sciences0302 clinical medicineInternal medicineMedicineCorticosteroidpneumoniaIn patient030212 general & internal medicinelcsh:R5-920business.industryCOVID-19General Medicinemedicine.diseasemethylprednisolonePneumoniaMethylprednisoloneGlucocorticoid therapyMedicineARDSRisk of deathSystematic ReviewCOVID-19 coronavirus corticosteroids methylprednisolone pneumonia ARDS SARS-Cov-2businesslcsh:Medicine (General)medicine.drug
researchProduct

Impact of Right Ventricular Dysfunction on Outcomes After Transcatheter Edge-to-Edge Repair for Secondary Mitral Regurgitation

2021

OBJECTIVES This study sought to assess the impact of right ventricular dysfunction (RVD) as defined by impaired right ventricular-to-pulmonary artery (RV-PA) coupling, on survival after edge-to-edge transcatheter mitral valve repair (TMVR) for severe secondary mitral regurgitation (SMR). BACKGROUND Conflicting data exist regarding the benefit of TMVR in severe SMR. A possible explanation could be differences in RVD. METHODS Using data from the EuroSMR (European Registry on Outcomes in Secondary Mitral Regurgitation) registry, this study compared the characteristics and outcomes of SMR patients undergoing TMVR, according to their RV-PA coupling, assessed by tricuspid annular plane systolic e…

medicine.medical_specialtyAdverse outcomesVentricular Dysfunction Right030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicine.arterymedicineHumansRadiology Nuclear Medicine and imagingIn patientCardiac Surgical Procedures610 Medicine & healthMitral regurgitationbusiness.industryMitral Valve InsufficiencyRight ventricular dysfunctionTreatment Outcomemedicine.anatomical_structurePulmonary arteryCardiologyTranscatheter mitral valve repairCardiology and Cardiovascular MedicinebusinessArteryJACC: Cardiovascular Imaging
researchProduct

Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

2020

Aims: \ud This retrospective analysis sought to identify markers that might distinguish between acute heart failure (HF) and worsening HF in chronic outpatients.\ud \ud Methods and Results: \ud The BIOSTAT‐CHF index cohort included 2516 patients with new or worsening HF symptoms: 1694 enrolled as inpatients (acute HF) and 822 as outpatients (worsening HF in chronic outpatients). A validation cohort included 935 inpatients and 803 outpatients. Multivariable models were developed in the index cohort using clinical characteristics, routine laboratory values, and proteomics data to examine which factors predict adverse outcomes in both conditions and to determine which factors differ between ac…

medicine.medical_specialtyAdverse outcomesacute heart failure treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemacute heart failure diagnosisInternal medicineOutpatientsDiagnosismedicineRetrospective analysisHumansAcute heart failure; acute heart failure diagnosis; acute heart failure treatmentRetrospective StudiesHeart Failurebusiness.industryTreatment developmentRoutine laboratoryAcute heart failurePrognosismedicine.diseaseR1[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHospitalizationTreatmentHeart failureChronic DiseaseCohortBiomarker (medicine)Cardiology and Cardiovascular MedicinebusinessCarbohydrate antigen
researchProduct

Diabetes Mellitus and Its Impact on Patient-Profile and In-Hospital Outcomes in Peripheral Artery Disease

2021

Background: In patients with peripheral artery disease (PAD), the impact of diabetes mellitus (DM) on patient-profile and adverse in-hospital events is not well investigated. Methods: The German nationwide inpatient sample 2005–2019 was used for this analysis. Hospitalized PAD patients were stratified for DM and the influence of DM on patient-profile and adverse in-hospital events was investigated. Results: Our study comprised 2,654,871 hospitalizations (54.3% aged ≥70 years, 36.7% females) of patients with PAD in Germany 2005–2019. Among these, 864,691 (32.6%) patients had DM and 76,716 (2.9%) died during hospitalization. Diabetic PAD patients revealed an aggravated cardiovascular profile …

medicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentRGeneral MedicineDiseasemedicine.diseaseperipheral artery diseaseArticlemyocardial infarctionHospital outcomesAmputationInternal medicineDiabetes mellitusamputationdiabetes mellitusmedicinePatient profileMedicineMyocardial infarctionAdverse effectbusinessJournal of Clinical Medicine
researchProduct

P124 The impact of the new American college of cardiology/american heart association (ACC/AHA) definition of hypertension on atherosclerotic vascular…

2020

Background The 2017 ACC/AHA guidelines define hypertension as ≥130/80 mmHg instead of ≥140/90 mmHg. Studies in systemic autoimmune diseases, where blood pressure (BP) is fluctuating over time, were not considered. Our aim was to assess the impact of the new definition on the prevalence and incidence of atherosclerotic vascular events (AVEs) in systemic lupus erythematosus (SLE). Patients-Methods SLE patients with at least two years of follow-up and no previous AVEs were divided in three groups (≥140/90 mmHg, 130–139/80–89 mmHg and Results 1532 patients satisfied the inclusion criteria (88.1% females, mean age at baseline 36.2±14.3 years, mean disease duration 6.1±6.3 years). The prevalence …

medicine.medical_specialtyBlood pressurebusiness.industryInternal medicineDisease durationIncidence (epidemiology)CardiologyMedicineCumulative incidenceMean agebusinessCardiovascular outcomesPoster presentations
researchProduct

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial

2021

Abstract Aims  Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. Methods and results  The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to eith…

medicine.medical_specialtyCardiac & Cardiovascular SystemsINHIBITIONRATIONALEPlaceboHYPERKALEMIAMECHANISMSHyperkalaemiaChronic kidney diseaseInternal medicineDiabetes mellitusType 2 diabetes mellitusEND-POINTSPost-hoc analysismedicineHumansCanagliflozinRenal Insufficiency Chronic1102 Cardiorespiratory Medicine and HaematologySodium-Glucose Transporter 2 InhibitorsCanagliflozinOUTCOMESScience & Technologybusiness.industryType 2 Diabetes Mellitus1103 Clinical Sciencesmedicine.diseaseCardiovascular System & HematologyDiabetes Mellitus Type 2Serum potassiumCardiovascular System & CardiologyPotassiumCardiology and Cardiovascular MedicinebusinessComplicationLife Sciences & BiomedicineSGLT2 inhibitorsKidney diseasemedicine.drugEuropean Heart Journal
researchProduct

SARS-CoV-2 Viral Load, IFNλ Polymorphisms and the Course of COVID-19: An Observational Study

2020

The course of SARS-CoV-2 infection ranges from asymptomatic to a multiorgan disease. In this observational study, we investigated SARS-CoV-2 infected subjects with defined outcomes, evaluating the relationship between viral load and single nucleotide polymorphisms of genes codifying for IFN&lambda

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)viruseslcsh:MedicineSingle-nucleotide polymorphismDiseaseSettore MED/42 - Igiene Generale E ApplicataLower riskAsymptomaticGastroenterologyArticle03 medical and health sciencessingle nucleotide polymorphisms0302 clinical medicinesingle nucleotide polymorphismSettore BIO/13 - Biologia ApplicataInterferonIFNλsInternal medicinemedicine030212 general & internal medicineskin and connective tissue diseasesCOVID-19 outcome030304 developmental biologySettore MED/12 - Gastroenterologia0303 health sciencesbusiness.industrySARS-CoV-2fungilcsh:RIFNλGeneral Medicinerespiratory tract diseasesCOVID-19 outcomesviral loadbody regionsObservational studymedicine.symptombusinessViral loadmedicine.drugJournal of Clinical Medicine
researchProduct